ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. is a New York–based oncology-named entity with approximately 20 employees; its primary domain is currently parked and no products, customers, management, or financial data are disclosed in the source material.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount11–50
- GTM typeB2B
- OfferingServices
ZIOPHARM Oncology, Inc. firmographics
Firmographics- Name
- ZIOPHARM Oncology, Inc.
- Website
- https://ziopharm.com
- Company type
- Private
- Headcount range
- 11–50 employees
- Short description
- ZIOPHARM Oncology, Inc. is a New York–based oncology-named entity with approximately 20 employees; its primary domain is currently parked and no products, customers, management, or financial data are disclosed in the source material.
- Ownership category
- akta.pro rank
ZIOPHARM Oncology, Inc. industry classification
Industry- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neuro-Oncology (HLAKAFAH)
ZIOPHARM Oncology, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
ZIOPHARM Oncology, Inc. product offering
Product offeringCore offering
No information is available about ZIOPHARM Oncology's core offerings. The ziopharm.com domain is parked with GoDaddy and contains no company content, products, pipeline, or service descriptions.
Differentiator
Problem solved
Functional benefit
ZIOPHARM Oncology, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ZIOPHARM Oncology, Inc. competitors and assessment
Company assessmentDirect peers
- Carisma Therapeutics: Carisma Therapeutics is the entity that absorbed ZIOPHARM Oncology via reverse merger, making it the most directly comparable successor entity. Both companies operated in the oncology cell therapy space with macrophage and CAR-T based approaches.
- Adaptimmune Therapeutics: Adaptimmune is a clinical-stage cell therapy company focused on engineered TCR therapies for solid tumors. It is comparable to ZIOPHARM as a similarly sized, oncology-focused cell therapy developer targeting difficult-to-treat cancers.
- Iovance Biotherapeutics: Iovance Biotherapeutics develops tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It is comparable as a clinical-to-commercial stage oncology cell therapy company working in similar indications.
- Allogene Therapeutics: Allogene develops allogeneic CAR T-cell therapies for hematologic and solid tumor malignancies. As a clinical-stage oncology cell therapy company, it operates in the same product category and target indications as ZIOPHARM's historical pipeline.
Emerging players
- Precision BioSciences: Precision BioSciences develops in vivo gene-edited cell therapies, including allogeneic CAR-T candidates for oncology. Its ARCUS platform addresses similar patient populations and indications to ZIOPHARM's historical work.
- Sana Biotechnology: Sana Biotechnology is a clinical-stage cell and gene therapy company with oncology applications. It is comparable as a peer in engineered cell therapy development targeting oncology indications.
- CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited cell therapies for oncology and hemoglobinopathies. Its gene-editing platform intersects with the engineered cell therapy approaches ZIOPHARM pursued in immuno-oncology.
- Cellectis: Cellectis is a clinical-stage gene-editing and CAR-T cell therapy company focused on oncology. It is comparable to ZIOPHARM as a similarly sized peer in the engineered cell therapy oncology space.
Broad incumbents
- Gilead Sciences (Kite Pharma): Gilead Sciences, through its Kite Pharma subsidiary, is a leading commercial-stage CAR-T cell therapy provider. It represents the broad incumbent benchmark for oncology cell therapy development and commercialization that smaller peers like ZIOPHARM aspire toward.
- Bristol-Myers Squibb: Bristol-Myers Squibb is a broad incumbent pharmaceutical company with a leading oncology franchise including cell therapies (Breyanzi, Abecma). It competes for talent, capital, and partnership opportunities in ZIOPHARM's therapeutic space.
Market position
Customer concentration
ZIOPHARM Oncology, Inc. social profiles
Digital presenceZIOPHARM Oncology, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
ZIOPHARM Oncology, Inc. leadership team
Management profileNumber of profiles
ZIOPHARM Oncology, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ZIOPHARM Oncology, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ZIOPHARM Oncology, Inc.
What does ZIOPHARM Oncology, Inc. do?
No information is available about ZIOPHARM Oncology's core offerings. The ziopharm.com domain is parked with GoDaddy and contains no company content, products, pipeline, or service descriptions.
When was ZIOPHARM Oncology, Inc. founded?
ZIOPHARM Oncology, Inc. was founded in -1. It employs 11 to 50 people.
Who are ZIOPHARM Oncology, Inc.'s main competitors?
Direct peers on record are Carisma Therapeutics, Adaptimmune Therapeutics, Iovance Biotherapeutics and Allogene Therapeutics. Emerging players are Precision BioSciences, Sana Biotechnology, CRISPR Therapeutics and Cellectis. Broad incumbents are Gilead Sciences (Kite Pharma) and Bristol-Myers Squibb.
Does ZIOPHARM Oncology, Inc. have an API?
No public API is recorded for ZIOPHARM Oncology, Inc..
What industry is ZIOPHARM Oncology, Inc. in?
Its primary akta.pro industry code is HLAKAFAH, Neuro-Oncology. Its NAICS code is 325412 and its SIC code is 2834.